1. Home
  2. CHE vs PTGX Comparison

CHE vs PTGX Comparison

Compare CHE & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CHE

Chemed Corp

HOLD

Current Price

$433.06

Market Cap

5.8B

Sector

Health Care

ML Signal

HOLD

Logo Protagonist Therapeutics Inc.

PTGX

Protagonist Therapeutics Inc.

HOLD

Current Price

$99.65

Market Cap

6.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHE
PTGX
Founded
1970
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Nursing Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.8B
6.4B
IPO Year
1994
2016

Fundamental Metrics

Financial Performance
Metric
CHE
PTGX
Price
$433.06
$99.65
Analyst Decision
Buy
Strong Buy
Analyst Count
4
13
Target Price
$501.50
$108.23
AVG Volume (30 Days)
193.5K
429.0K
Earning Date
04-23-2026
05-07-2026
Dividend Yield
0.57%
N/A
EPS Growth
N/A
N/A
EPS
4.84
0.05
Revenue
$2,529,978,000.00
N/A
Revenue This Year
$6.56
$874.25
Revenue Next Year
$6.23
N/A
P/E Ratio
$90.74
$1,996.00
Revenue Growth
4.06
N/A
52 Week Low
$365.21
$47.53
52 Week High
$572.23
$107.84

Technical Indicators

Market Signals
Indicator
CHE
PTGX
Relative Strength Index (RSI) 58.18 47.90
Support Level $423.89 $96.36
Resistance Level $455.83 $100.00
Average True Range (ATR) 11.55 4.06
MACD -0.83 -0.18
Stochastic Oscillator 68.65 33.37

Price Performance

Historical Comparison
CHE
PTGX

About CHE Chemed Corp

Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. The company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.

About PTGX Protagonist Therapeutics Inc.

Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.

Share on Social Networks: